Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2001;103:1899-1905

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huckle, W. R.
Right arrow Articles by Johnson, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huckle, W. R.
Right arrow Articles by Johnson, R. G., Jr
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Animal models of human disease
Right arrow Smooth muscle proliferation and differentiation
Right arrow Coronary circulation
Right arrow Receptor pharmacology

(Circulation. 2001;103:1899.)
© 2001 American Heart Association, Inc.


Basic Science Reports

Effects of L-749,329, an ETA/ETB Endothelin Receptor Antagonist, in a Porcine Coronary Artery Injury Model of Vascular Restenosis

William R. Huckle, PhD; Marlene D. Drag, DVM; Wayne R. Acker, BS; Michele Powers, BS; Rosemary C. McFall, BS; Daniel J. Holder, PhD; Thomas F. Walsh, PhD; Robert S. Schwartz, MD; William J. Greenlee, PhD; Robert G. Johnson, Jr, MD, PhD

From the Departments of Pharmacology (W.R.H., R.C.M., R.G.J.), Laboratory Animal Resources (M.D.D., W.R.A., M.P.), Biometrics (D.J.H.), and Exploratory Chemistry (T.F.W., W.J.G.), Merck Research Labs, West Point, Pa, and Division of Cardiovascular Diseases (R.S.S.), Department of Medicine, Mayo Clinic and Foundation, Rochester, Minn.

Correspondence to Dr William R. Huckle, Department of Biomedical Sciences & Pathobiology (0442), Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061. E-mail wrhuckle{at}vt.edu

Background—Previous studies in animal models of angioplasty have suggested a role in neointimal hyperplasia for endothelins (ETs), potent vasoconstricting peptides that also exert growth-promoting effects. The present studies were undertaken to test the hypothesis that endothelin receptor blockade can reduce neointimal thickening in injured porcine coronary arteries.

Methods and Results—An ETA/ETB antagonist, L-749,329, was evaluated as an inhibitor of intimal thickening in a porcine balloon/stent model of coronary artery injury. L-749,329 competitively inhibited [125I]ET-1 binding to porcine ETA (IC50 {approx}0.3 nmol/L) or ETB (IC50 {approx}20 nmol/L) receptors and inhibited ET-1–stimulated signaling in cell culture. In anesthetized pigs, big ET-1–stimulated increases in systemic blood pressure were totally inhibited after intravenous infusion of L-749,329 (>=0.2 mg · kg-1 · h-1). In vascular injury studies, pigs were treated with vehicle or L-749,329 (1 mg · kg-1 · h-1) beginning 2 days before and continuing 28 days after experimental angioplasty. Left anterior descending, left circumflex, and/or right coronary arteries were injured by inflation of an angioplasty balloon wrapped with a coiled metallic stent. After 28 days, mean neointimal thickness in the L-749,329–treated group was reduced by 9.0% compared with vehicle-treated controls, but this effect was not statistically significant (P=0.13).

Conclusions—Blockade of endothelin receptors for 28 days with only a mixed ETA/ETB receptor antagonist is insufficient to substantially inhibit intimal hyperplasia after balloon/stent coronary artery injury in the pig, in contrast to results with a selective ETA antagonist. The effects of selective or mixed ETA/ETB antagonists in diseased vessels remain to be determined in this model.


Key Words: restenosis • endothelin • coronary disease • angioplasty




This article has been cited by other articles:


Home page
CirculationHome page
N. Murakoshi, T. Miyauchi, Y. Kakinuma, T. Ohuchi, K. Goto, M. Yanagisawa, and I. Yamaguchi
Vascular Endothelin-B Receptor System In Vivo Plays a Favorable Inhibitory Role in Vascular Remodeling After Injury Revealed by Endothelin-B Receptor-Knockout Mice
Circulation, October 8, 2002; 106(15): 1991 - 1998.
[Abstract] [Full Text] [PDF]